Alaska Airlines and UP.Labs Launch Odysee, an AI-Enabled Startup Taking a New Approach to Schedule Optimization
One year after announcing their partnership to solve business challenges through innovation, Alaska Airlines and UP.Labs have officially announced their first new startup, Odysee, at the UP.Summit. Odysee, which launched with $5M in seed funding led by UP.Partners, is focused on lending powerful AI and computing power to inform real-time tradeoff decisions in planning for and managing operational logistics, starting with scheduling. The platform will ensure the best use of each aircraft asset and the interconnections between them, empowering teams to more effectively optimize one of the most complex areas of an airline’s business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241002853148/en/
This AI-powered flight schedule optimization solution marks a significant milestone in the journey that began at last year’s UP.Summit. Last year, the two companies announced their partnership and set a vision to solve core strategic challenges for the aviation industry with new companies that help unlock the future in transportation and mobility.
“What sets Odysee apart is its ability to help airline schedulers assess the various tradeoffs that come with certain schedule changes, allowing them to make more informed choices in building comprehensive flight schedules,” said Odysee Chief Executive Officer Steve Casley. “Our team is excited about the power and efficiency this technology will provide to Alaska Airlines and all future customers and the opportunity to continue building out its functionality.”
Odysee utilizes an operations research-led approach to build flight schedules and rapidly quantify the impacts of schedule changes on revenue, profitability and reliability. The platform can run hundreds of simulations within seconds to provide accurate flight-level insights to stress-test a future schedule. This tool can assess more options and evaluate more variables than the human brain – giving teams the opportunity to make more informed decisions.
“As CEO and a former COO, I know that configuring an airline to use each airplane optimally is a key lever for operational reliability, a remarkable travel experience for our guests, and maximizing revenue,” said Alaska Airlines Chief Executive Officer Ben Minicucci. “I am thrilled that Odysee, the first company launched through our partnership with UP.Labs, leverages artificial intelligence to help our teams put our airplanes in the right place, at the right time.”
The partnership between UP.Labs and Alaska Airlines was established as part of Alaska Star Ventures, Alaska Airlines’ investment arm and is aligned with Alaska’s commitment to innovation and sustainability. Over the next three years, the partnership will launch additional startups focused on solving key challenges in aviation and mobility.
UP.Labs is a venture lab and a core part of the UP.Partners ecosystem, which also includes mobility investment fund UP.Ventures and the UP.Summit, an invite-only mobility event that brings together 300 of the world’s most innovative minds rethinking the future of transportation.
“The launch of Odysee marks an exciting milestone, uniting the strengths of UP.Labs and Alaska Airlines to create a startup that revolutionizes how flight schedules are built, analyzed and optimized,” said John Kuolt, Founder and CEO of UP.Labs. “By combining our expertise and shared vision, we’re paving the way for new opportunities, driving growth, and setting a new standard in our industry.”
About Alaska Airlines
Alaska Air Group, Inc. is based in Seattle and comprised of subsidiaries Alaska Airlines, Hawaiian Holdings, Inc., Horizon Air and McGee Air Services. With our recent acquisition of Hawaiian Airlines, we now serve more than 140 destinations throughout North America, Central America, Asia and across the Pacific. We are committed to safety, remarkable customer care, operational excellence, financial performance and sustainability. Alaska Airlines is a member of the oneworld Alliance. With oneworld and our additional global partners, our guests have more choices than ever to purchase, earn or redeem on alaskaair.com across 30 airlines and more than 1,000 worldwide destinations. Book travel throughout the Pacific on Hawaiian Airlines at hawaiianairlines.com. Learn more about Alaska Airlines at news.alaskaair.com and Hawaiian Airlines at newsroom.hawaiianairlines.com/blog. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as “ALK.”
About UP.Partners
UP.Partners is Transforming the Moving World by building and investing in companies that move people and goods cleaner, faster, safer, and at lower cost — on the ground, in the air, on the sea, and in space. The multi-strategy firm achieves this goal through its unique and virtuous ecosystem encompassing UP.Ventures, UP.Labs, and UP.Summit. UP.Ventures invests in companies and technologies to enable the future of mobility, working with some of the world’s most innovative investors and entrepreneurs. With flagship launch partner Porsche, UP.Labs is a first-of-its-kind venture lab, partnering with the world’s largest corporations to identify the most pressing challenges that they, and broader society, face. The UP.Summit is an invitation-only experience co-hosted with Tom and Steuart Walton and Ross Perot Jr., in Bentonville, AR and Dallas/Ft. Worth, TX respectively, bringing together the world’s most innovative minds to rethink the future of transportation. For more information, visit www.UP.partners or follow on Twitter @UpPartnersVC or LinkedIn.
About UP.Labs
UP.Labs is a first of its kind Venture Lab using a new venture model to solve core problems for the world’s most important corporations in the mobility world. By bringing together world-class business leaders, investors and corporate partners, UP.Labs solves industry problems for corporations who have the scale and resources but cannot do it on their own. Recognizing that transportation is the underlying fabric of society, UP.Labs utilizes these strategic partnerships to rapidly ideate, build and scale disruptive startups transforming the way we move people and goods to be cleaner, faster, and safer. To learn more visit https://up.partners/labs/.
About UP.Summit
UP.Summit is an annual, invitation-only gathering of the world’s most innovative minds rethinking the future of transportation. Some of the most impactful investors, entrepreneurs, and leaders in policy, defense, transportation and mobility companies gather at the summit each year with the goal of moving people and goods in cleaner, faster, safer, and at lower-cost ways — on the ground, in the air, on the sea, and in space. UP.Summit was founded in 2017 and is jointly organized by UP.Partners, Tom and Steuart Walton, and Ross Perot Jr.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241002853148/en/
Contacts
Mollie Gonzalez
mollie@bulleitgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release
Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom